Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2006-03-08 15:00:54 UTC |
---|
Update Date | 2021-09-14 15:45:51 UTC |
---|
HMDB ID | HMDB0001897 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Substance P |
---|
Description | Substance P (SP), is an 11-amino acid neuropeptide. SP is a member of the tachykinin family of peptides because it induces rapid smooth muscle contraction in guinea pig ileum and rat duodenum. Other members of the tachykinin family, sharing common carboxyl terminal Phe-X-Gly-Leu-met-NH2 sequences in mammals, include neurokinin A and neurokinin B. In mammals, tachykinins are produced by two genes, preprotachykinin-A (PPT-A) and preprotachykinin-B (PPT-B), and SP is a product of the PPT-A gene. SP is localized in the central nervous system as well as in several peripheral tissues, including the entire length of the gastrointestinal tract as well as the colon. The main sources of SP in the gut include the myenteric and submucosal plexus, intrinsic sensory neurons, as well as sensory neurons originating from the dorsal root ganglia. A newly identified gene, preprotachykinin C gene, encodes for the sequence of a new preprotachykinin protein designated hemokinin (HK) and produced primarily by hematopoietic cells. HK binds with high selectivity to NK-1R and has similar in vivo potency to SP. Like SP, HK is an 11-amino acid peptide having ~55% amino acid similarity to SP. The effects of SP are mediated by three different G-protein-coupled receptors (GPCRs), namely neurokinin (NK)-1, 2, and 3. SP binds with high affinity to NK-1 receptor (NK-1R), and with low affinity to NK-2 and 3 receptors. NK-1 receptors are present in both small intestine and colon of animals and humans and are localized in a variety of cells, including nerves, smooth muscle, immune cells, glands, endothelial cells, as well as epithelial cells. Although NK-1 receptors have been associated with several intestinal pathophysiologic conditions (see below), NK-2 receptors have been linked mostly with circular muscle contraction, and are localized in circular muscle and muscularis mucosae. Although NK-2 receptors are present predominantly on smooth muscle and, like NK-1, can affect gut motility, NK-3 receptors are expressed predominantly in neurons and can stimulate or diminish muscle contraction indirectly following SP binding to neuronal cells in the submucosal and myenteric nerve plexuses of the gastrointestinal tract. NK-3 receptors also provide slow excitatory synaptic input to neurons in ganglia of the sphincter of Oddi. Thus, both NK-2 and NK-3 receptors affect motility responses in the GI, but there is very little evidence that they are involved in neuroimmune interactions. (PMID: 17192554 ). |
---|
Structure | CSCC[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)CNC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O InChI=1S/C63H98N18O13S/c1-37(2)33-45(57(89)74-41(53(68)85)27-32-95-3)73-52(84)36-72-54(86)46(34-38-15-6-4-7-16-38)78-58(90)47(35-39-17-8-5-9-18-39)79-56(88)42(23-25-50(66)82)75-55(87)43(24-26-51(67)83)76-59(91)49-22-14-31-81(49)62(94)44(20-10-11-28-64)77-60(92)48-21-13-30-80(48)61(93)40(65)19-12-29-71-63(69)70/h4-9,15-18,37,40-49H,10-14,19-36,64-65H2,1-3H3,(H2,66,82)(H2,67,83)(H2,68,85)(H,72,86)(H,73,84)(H,74,89)(H,75,87)(H,76,91)(H,77,92)(H,78,90)(H,79,88)(H4,69,70,71)/t40-,41-,42-,43+,44-,45+,46+,47+,48+,49-/m0/s1 |
---|
Synonyms | Value | Source |
---|
Arg-pro-lys-pro-GLN-GLN-phe-phe-gly-leu-met-NH2 | HMDB | (2S)-2-{[(2R)-2-({[(2S)-1-[(2S)-6-amino-2-({[(2R)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)hexanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene]amino}-N-[(1R)-1-{[(1R)-1-[({[(1R)-1-{[(1S)-1-(C-hydroxycarbonimidoyl)-3-(methylsulfanyl)propyl]-C-hydroxycarbonimidoyl}-3-methylbutyl]-C-hydroxycarbonimidoyl}methyl)-C-hydroxycarbonimidoyl]-2-phenylethyl]-C-hydroxycarbonimidoyl}-2-phenylethyl]pentanediimidate | HMDB | (2S)-2-{[(2R)-2-({[(2S)-1-[(2S)-6-amino-2-({[(2R)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)hexanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene]amino}-N-[(1R)-1-{[(1R)-1-[({[(1R)-1-{[(1S)-1-(C-hydroxycarbonimidoyl)-3-(methylsulphanyl)propyl]-C-hydroxycarbonimidoyl}-3-methylbutyl]-C-hydroxycarbonimidoyl}methyl)-C-hydroxycarbonimidoyl]-2-phenylethyl]-C-hydroxycarbonimidoyl}-2-phenylethyl]pentanediimidate | HMDB | (2S)-2-{[(2R)-2-({[(2S)-1-[(2S)-6-amino-2-({[(2R)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)hexanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene]amino}-N-[(1R)-1-{[(1R)-1-[({[(1R)-1-{[(1S)-1-(C-hydroxycarbonimidoyl)-3-(methylsulphanyl)propyl]-C-hydroxycarbonimidoyl}-3-methylbutyl]-C-hydroxycarbonimidoyl}methyl)-C-hydroxycarbonimidoyl]-2-phenylethyl]-C-hydroxycarbonimidoyl}-2-phenylethyl]pentanediimidic acid | HMDB |
|
---|
Chemical Formula | C63H98N18O13S |
---|
Average Molecular Weight | 1347.63 |
---|
Monoisotopic Molecular Weight | 1346.728146002 |
---|
IUPAC Name | (2S)-2-[(2R)-2-{[(2S)-1-[(2S)-6-amino-2-{[(2R)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]formamido}hexanoyl]pyrrolidin-2-yl]formamido}-4-carbamoylbutanamido]-N-[(1R)-1-{[(1R)-1-[({[(1R)-1-{[(1S)-1-carbamoyl-3-(methylsulfanyl)propyl]carbamoyl}-3-methylbutyl]carbamoyl}methyl)carbamoyl]-2-phenylethyl]carbamoyl}-2-phenylethyl]pentanediamide |
---|
Traditional Name | (2S)-2-[(2R)-2-{[(2S)-1-[(2S)-6-amino-2-{[(2R)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]formamido}hexanoyl]pyrrolidin-2-yl]formamido}-4-carbamoylbutanamido]-N-[(1R)-1-{[(1R)-1-[({[(1R)-1-{[(1S)-1-carbamoyl-3-(methylsulfanyl)propyl]carbamoyl}-3-methylbutyl]carbamoyl}methyl)carbamoyl]-2-phenylethyl]carbamoyl}-2-phenylethyl]pentanediamide |
---|
CAS Registry Number | 33507-63-0 |
---|
SMILES | CSCC[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)CNC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O |
---|
InChI Identifier | InChI=1S/C63H98N18O13S/c1-37(2)33-45(57(89)74-41(53(68)85)27-32-95-3)73-52(84)36-72-54(86)46(34-38-15-6-4-7-16-38)78-58(90)47(35-39-17-8-5-9-18-39)79-56(88)42(23-25-50(66)82)75-55(87)43(24-26-51(67)83)76-59(91)49-22-14-31-81(49)62(94)44(20-10-11-28-64)77-60(92)48-21-13-30-80(48)61(93)40(65)19-12-29-71-63(69)70/h4-9,15-18,37,40-49H,10-14,19-36,64-65H2,1-3H3,(H2,66,82)(H2,67,83)(H2,68,85)(H,72,86)(H,73,84)(H,74,89)(H,75,87)(H,76,91)(H,77,92)(H,78,90)(H,79,88)(H4,69,70,71)/t40-,41-,42-,43+,44-,45+,46+,47+,48+,49-/m0/s1 |
---|
InChI Key | ADNPLDHMAVUMIW-SGTHPBLKSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as tocopherols. These are vitamin E derivatives containing a saturated trimethyltridecyl chain attached to the carbon C6 atom of a benzopyran ring system. The differ from tocotrienols that contain an unsaturated trimethyltrideca-3,7,11-trien-1-yl chain. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Prenol lipids |
---|
Sub Class | Quinone and hydroquinone lipids |
---|
Direct Parent | Tocopherols |
---|
Alternative Parents | |
---|
Substituents | - Tocopherol
- Diterpenoid
- 1-benzopyran
- Benzopyran
- Chromane
- Alkyl aryl ether
- Benzenoid
- Oxacycle
- Organoheterocyclic compound
- Ether
- Organic oxygen compound
- Hydrocarbon derivative
- Organooxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 148 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredictor | Adduct Type | CCS Value (Å2) | Reference |
---|
DeepCCS | [M+H]+ | 350.625 | 30932474 | DeepCCS | [M-H]- | 348.901 | 30932474 | DeepCCS | [M-2H]- | 382.933 | 30932474 | DeepCCS | [M+Na]+ | 356.914 | 30932474 |
Predicted Kovats Retention IndicesNot Available |
---|
Spectra |
---|
| MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Substance P 10V, Positive-QTOF | splash10-02wa-1319101010-209f8038eedc515a4d6f | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Substance P 20V, Positive-QTOF | splash10-02ta-2729101110-7d4d3932d047407e1218 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Substance P 40V, Positive-QTOF | splash10-02mj-9835202000-3628a96e37d0d507d9c7 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Substance P 10V, Negative-QTOF | splash10-0f92-6079000000-c6a896a4135dad2d4620 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Substance P 20V, Negative-QTOF | splash10-0002-9133000000-514803d766a008324128 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Substance P 40V, Negative-QTOF | splash10-0002-9101000000-1af52acc0df0cbc52a65 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Substance P 10V, Positive-QTOF | splash10-000t-0129000100-2f2b29bac4d06feba232 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Substance P 20V, Positive-QTOF | splash10-007o-7595010000-13664c74323543ccdd59 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Substance P 40V, Positive-QTOF | splash10-03k9-9320000120-1079eed36e2a21c18dea | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Substance P 10V, Negative-QTOF | splash10-0udj-2049000000-4cebe1eb15b90be2040a | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Substance P 20V, Negative-QTOF | splash10-002b-9025000000-5643582ce89021214629 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Substance P 40V, Negative-QTOF | splash10-002g-9720010000-9e20245db6eb8a6287f3 | 2021-09-24 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum |
| Show more...
---|
Biological Properties |
---|
Cellular Locations | Not Available |
---|
Biospecimen Locations | - Blood
- Cerebrospinal Fluid (CSF)
- Urine
|
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.0000036 +/- 0.0000018 uM | Adult (>18 years old) | Both | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.323-1.07 uM | Not Specified | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.000007 +/- 0.0000006 uM | Adult (>18 years old) | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.000141 +/- 0.0000142 uM | Newborn (0-30 days old) | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.022673 +/- 0.00834 uM | Not Specified | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0227 +/- 0.0083 uM | Not Specified | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00005 +/- 0.0000023 uM | Children (1-13 years old) | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0000095 +/- 0.0000015 uM | Adult (>18 years old) | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0000196 +/- 0.0000032 uM | Not Specified | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0000144 +/- 0.0000042 uM | Not Specified | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0000007425 +/- 0.00000007425 uM | Not Specified | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0000008910 +/- 0.0000005940 uM | Not Specified | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0000123 +/- 0.0000028 uM | Adult (>18 years old) | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00002339 +/- 0.000001188 uM | Adult (>18 years old) | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00002354 +/- 0.000001559 uM | Adult (>18 years old) | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00002309 +/- 0.000001782 uM | Adult (>18 years old) | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0000439 +/- 0.0000099 uM | Adult (>18 years old) | Not Specified | Normal | | details |
| Show more...
---|
Abnormal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.0000049 +/- 0.0000027 uM | Adult (>18 years old) | Both | Migraine | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 1.37-16.3 uM | Not Specified | Not Specified | Cobalamin deficiency | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.000864 +/- 0.0003576 uM | Newborn (0-30 days old) | Not Specified | Spina Bifida | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.15 uM | Not Specified | Not Specified | Spina Bifida | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00025 +/- 0.0000282 uM | Newborn (0-30 days old) | Not Specified | Premature | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 1.41e-4 +/- 1.42e-05 uM | Newborn (0-30 days old) | Not Specified | Full term newborn | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0000361 +/- 0.0000027 uM | Not Specified | Not Specified | Fibromyalgia | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0000401 +/- 0.0000027 uM | Adult (>18 years old) | Not Specified | Fibromyalgia | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0000292 +/- 0.000005 uM | Not Specified | Not Specified | Fibromyalgia | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0000351 +/- 0.0000032 uM | Not Specified | Not Specified | Fibromyalgia | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0000192 +/- 0.0000067 uM | Not Specified | Not Specified | Sleep Apnea Syndrome | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0000009653 +/- 0.0000008910 uM | Not Specified | Not Specified | Chronic headache | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0000005198 +/- 0.0000003713 uM | Not Specified | Not Specified | Chronic headache | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0000199 +/- 0.0000039 uM | Adult (>18 years old) | Not Specified | Term Pregnancy | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00002176 +/- 0.000001188 uM | Adult (>18 years old) | Not Specified | Alzheimer's disease | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00003111 +/- 0.000002822 uM | Adult (>18 years old) | Not Specified | Alzheimer's disease | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00002658 +/- 0.000002153 uM | Adult (>18 years old) | Not Specified | Non-Alzheimer dementias | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00002562 +/- 0.0000009653 uM | Adult (>18 years old) | Not Specified | Neurological disorders without cognitive impairment | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00002770 +/- 0.0000020000 uM | Adult (>18 years old) | Not Specified | Alzheimer's Disease | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0000303 +/- 0.0000078 uM | Adult (>18 years old) | Not Specified | Narcolepsy | | details | Urine | Detected and Quantified | 0.0000098 +/- 0.0000036 umol/mmol creatinine | Adult (>18 years old) | Female | Malignant solid neoplasm | | details | Urine | Detected and Quantified | 0.000011 (0.0000005-0.000036) umol/mmol creatinine | Adult (>18 years old) | Both | Cisplatin containing chemotherapy | | details |
| Show more...
---|
Associated Disorders and Diseases |
---|
Disease References | Migraine |
---|
- Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K: Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain. 2007 Apr;128(3):209-14. Epub 2006 Nov 22. [PubMed:17123735 ]
| Vitamin B12 deficiency |
---|
- Allen RH, Stabler SP, Savage DG, Lindenbaum J: Elevation of 2-methylcitric acid I and II levels in serum, urine, and cerebrospinal fluid of patients with cobalamin deficiency. Metabolism. 1993 Aug;42(8):978-88. [PubMed:8345822 ]
| Spina Bifida |
---|
- Tam PK, Lister J: Elevation of cerebrospinal fluid substance P concentrations in spina bifida. Z Kinderchir. 1984 Dec;39 Suppl 2:89-90. [PubMed:6084371 ]
| Fibromyalgia |
---|
- Vaeroy H, Helle R, Forre O, Kass E, Terenius L: Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain. 1988 Jan;32(1):21-6. [PubMed:2448729 ]
- Vaeroy H, Sakurada T, Forre O, Kass E, Terenius L: Modulation of pain in fibromyalgia (fibrositis syndrome): cerebrospinal fluid (CSF) investigation of pain related neuropeptides with special reference to calcitonin gene related peptide (CGRP). J Rheumatol Suppl. 1989 Nov;19:94-7. [PubMed:2481742 ]
| Sleep apnea |
---|
- Gislason T, Hedner J, Terenius L, Bisette G, Nemeroff CB: Substance P, thyrotropin-releasing hormone, and monoamine metabolites in cerebrospinal fluid in sleep apnea patients. Am Rev Respir Dis. 1992 Sep;146(3):784-6. [PubMed:1381567 ]
| Alzheimer's disease |
---|
- Rosler N, Wichart I, Jellinger KA: Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients. J Neural Transm (Vienna). 2001;108(2):231-46. [PubMed:11314776 ]
| Narcolepsy |
---|
- Strittmatter M, Isenberg E, Grauer MT, Hamann G, Schimrigk K: CSF substance P somatostatin and monoaminergic transmitter metabolites in patients with narcolepsy. Neurosci Lett. 1996 Nov 1;218(2):99-102. [PubMed:8945737 ]
|
|
---|
Associated OMIM IDs | |
---|
External Links |
---|
DrugBank ID | Not Available |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB002259 |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 23215821 |
---|
KEGG Compound ID | Not Available |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Substance P |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 44359816 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 332416 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | MDB00000355 |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Egorova, S. V.; Akhrem, A. A. Synthesis of substance P. Vestsi Akademii Navuk BSSR, Seryya Khimichnykh Navuk (1989), (1), 46-51. |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Koon HW, Pothoulakis C: Immunomodulatory properties of substance P: the gastrointestinal system as a model. Ann N Y Acad Sci. 2006 Nov;1088:23-40. [PubMed:17192554 ]
- Rothstein RD, Johnson E, Ouyang A: Substance P: mechanism of action and receptor distribution at the feline ileocecal sphincter region. Am J Physiol. 1989 Sep;257(3 Pt 1):G447-53. [PubMed:2476938 ]
- Grimsholm O, Rantapaa-Dahlqvist S, Dalen T, Forsgren S: Observations favouring the occurrence of local production and marked effects of bombesin/gastrin-releasing peptide in the synovial tissue of the human knee joint--comparisons with substance P and the NK-1 receptor. Neuropeptides. 2008 Apr;42(2):133-45. doi: 10.1016/j.npep.2007.12.008. [PubMed:18289674 ]
- Sequence Information [Link]
|
---|